Clinical trial
Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma…
NCT00165477 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165477 |
|---|---|
| Title | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme |
| Official title | Phase II Study of Lenalidomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme. |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Celgene Corporation Industry Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital University of Virginia |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Gliosarcoma, Malignant Gliomas |
| Intervention type | Drug, Radiation |
| Interventions | lenalidomide, Radiation |
| Enrollment | 23 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2007 |
| Completion | Jul 1, 2009 |
| First posted | Sep 14, 2005 |
| Last update posted | Mar 10, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: